The global burden of malaria remains significant, with an estimated 241 million cases and 627,000 deaths reported annually. This ongoing crisis calls for ...

Antimalarial drug resistance is a pressing issue in combating the spread of malaria worldwide. In a new study, researchers discovered a key process where malarial parasites take up a human blood cell ...

LONDON (Reuters) -A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final ...

Malaria is a major global health problem. The therapeutic options are scarce and challenged by the emergence of resistant parasite strains, which causes a ...

Malaria is a constant threat for nearly half of the world’s population, and people who travel to those areas are also at risk. Although the short-term side effects of prophylactic drugs are ...

Learn more Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic ...

GENEVA (AP) — Switzerland's medical products authority has granted the first approval for a malaria medicine designed for small infants, touted as an advance against a disease that takes hundreds of ...

Malaria represents one of the most serious threats to human health worldwide, and preventing and curing this parasitic disease still depends predominantly on the administration of a small number of ...

Dr. Reddy’s and its CRDMO arm Aurigene Pharmaceutical Services have signed a non-binding Memorandum of Understanding with Kainomyx, a U.S.-based company with a platform that helps target cytoskeletal ...

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as well as some cancers. In these diseases, a mutation in the genetic code ...

Cardiac fibrosis is a frequent comorbidity in many diseases, such as ischemic heart failure or diabetes mellitus, contributing to increased mortality. No drugs are approved for cardiac fibrosis and ...